Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\[s\] it aims to answer are: * the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids * the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids

Trial Details

NCT ID
NCT06671548
Phase
PHASE3
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Relugolix
  • Relugolix placebo
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Premenopausal female aged 18 or older
  • Diagnosis of uterine fibroids confirmed by transvaginal/rectal ultrasound during the screening period
  • Heavy menstrual bleeding caused by uterine fibroids
  • Breast ultrasound results during the screening period meet the BI-RADS classification of 1 to 3

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →